Hospital Mater Dei S.A. (BVMF:MATD3)
Brazil flag Brazil · Delayed Price · Currency is BRL
5.30
+0.12 (2.32%)
At close: Nov 17, 2026
← View all transcripts

Earnings Call: Q3 2026

Nov 10, 2026

Summary

Q3 net revenue rose 16.3% YoY to BRL 660m, with record EBITDA of BRL 148.2m and a 22.5% margin. Oncology and higher-complexity care drove growth; deleveraging remains the priority.

Operator

Gentlemen, please be welcome to our third quarter earnings call for Mater Dei. We have our CFO and Director of Relations with Investors, and our CEO. This video conference is being recorded and will be made available on the company's website, where the investors relations are after it is ended. In order to access the simultaneous translation, please click on the globe. The website will have the presentation available.

We would like to inform you that any declarations or statements on future events are subject to risks and uncertainties, which may make some of these expectations not happen or be different than expected. These are opinions based on the date in which they are made, and the company is not obliged to carry them out. After the presentation, we will begin the questions and answers session.

In case you would like to ask any questions, please raise your hand so we will open the audio after. If you would like to send a question through the chat, we would like to ask you to tell us your name. I pass the floor to José Henrique to begin the presentation.

José Henrique
CEO, Hospital Mater Dei

Good afternoon to all. Before we begin, I would like to apologize for my voice. I am a little bit hoarse today. Maybe the call won't be as perfect, but I will do what I can to share all of the messages to you. When we begin this presentation, I always like to open with a special thanks to those who build our trajectory on a daily basis. First, our board for the support and strategic guidance which guide the Rede Mater Dei to a perennial and sustainable future.

I would like to also thank our managers and employers in general, to the physicians and members of the clinical body of the Rede Mater Dei f or the symbiosis that we have between disciplines and management and essential assistance. Essential assistance is the foundation to overcome the challenges and deliver top-notch medical care.

I would also like to thank the partner companies for the reciprocity and the relationship of trust built throughout the chain of value. Finally, I would like to thank all of the shareholders of the Mater Dei company and who believe in us and in our thesis. On the results, the first quarter of 2026 was marked by breaking away from various financial barriers and conquering many new results.

For the first time in the Rede Mater Dei , we passed the level of BRL 700 million in gross earnings, and with net earnings, we also went over BRL 650 million and reached, in this quarter, BRL 660 million. This net revenue is an expressive increase of 16% in relation to what we reached in the third quarter of 2025, and 7.5% more in relation to the second quarter of the year of 2026.

This new level of revenue is directly connected to the increase of our average ticket. Once again, we were able to overcome a historical barrier. Our average ticket went from BRL 3 million per bed used, reaching BRL 3.06 million, which represents a leap of almost 15% in the same period of last year, and 6.5% from the first semester of 2026.

Much further from anything that may happen by chance, this is an expressive, tangible result of all of our work and represents the maturity of our work carried out with absolute rigor with our strategic guidance. We have strategic guidance that we elaborated at the end of 2024 with relevant fronts, and every year, we funnel in the battles that are the more relevant battles for the strategic discipline of the company, and we have been able, as a network and as leaders, to battle each of these battles with absolute discipline and rigor.

One of the main strategies is the continued increase of high-complexity services, and here, I must highlight oncology. We gave another important step to inaugurate our new space of oncology in Santo Agostinho. That is why all of our units in Belo Horizonte and the metropolitan region now can offer oncological and ambulatory care structured with integrated care, cutting-edge technology, and personalized care.

As I already mentioned on previous occasions, it is important to reiterate that the specialty of oncology maintains a rhythm of expansion 2x higher than the consolidated revenue of the network. The impact of the strategy of high complexity is visible once again in this semester, in this trimester, in this quarter.

In Salvador, we had an expressive increase of 425% of oncological patients, 13% increase in surgical procedures compared to 2025. This clearly demonstrates how a [inaudible] from Salvador already has its space in medicine in the north and the northeast of the country, consolidating itself as one of the main institutions in that region.

In Mater Dei Nova Lima, the growth of oncological patients was 200%, besides an increase of 24%. It is higher than the previous year. With the new clients acquired of oncological patients, it increased 104% compared to the same quarter of the last year. All of this is pushed forward by a model of excellence and a cutting-edge structure that attracts our use in an organic way.

We have massively invested in technology, and we began to use our electronic medical record in the region of Belo Horizonte, allowing our physicians to be able to focus more on the care and safety of the patients, besides potentializing our lines of care, increasing in a sustainable way all of our units. These technologies will also be applied to the other networks as pre-established and will be implemented in all of our units.

We also increased our capacity with a new robot, Da Vinci, so now we have the presence of robotic surgeries in all of the states and in all of the hubs that we operate in. Besides that, another mark of our assistance is the first application of the CAR-T cells, consolidating our unit as the only center in Minas Gerais to offer this therapy.

We are advancing very quickly, delivering what we have in most innovative in all areas of medicine. With the advance of complexity and revenue, we have been able to reach 31.6% in our gross margin, the first time we passed the mark of 31% ever since the first quarter of 2024, a period in which we did not have any impact from the floor of nursing.

We also are 3 percentage points ahead of the same period of 2025 and 2.5 percentage points from the third semester of 2025, and this is an equivocal proof of our capacity and operation. We have elevated access with the rigorous control to be able to transform scale and efficiency into productivity and cost dilution in our vision. This is the formula to grow with efficiency, generating value, but especially assistance value to our patients, differentiating the Rede Mater Dei in each of the regions where we are placed.

In EBITDA, we went from BRL 140 million and reached almost BRL 150 million, getting a record EBITDA of BRL 148.2 million in the third quarter of 2026, and 7% against the second quarter of 2026. Annualizing our performance in the last period, we have BRL 530 million, which is higher than BRL 90 million in the results of 2025.

Our EBITDA margin reached 22.5%, representing evolution of 0.3 percentage points in the comparison with the third quarter and 2025. This strong operational result connected to our disciplined approach of working capital was very important to reduce our net debt, which closed the quarter in BRL 331 million with an improvement of BRL 30 million in the quarter.

Without considering the lines of remuneration to the shareholders, such as repurchasing the dividends, we would have reduced our net debt in BRL 71 million in the last 12 months, something that is fundamental to the sustainability of our institution. Our leverage index went down to a level that makes it very clear that there is a balance and financial health of the company, proving our capacity of deleveraging even in a period and in a very challenging macroeconomic scenario of high-interest rates.

This is the main direction for our company to capture capital. Finally, I would like to reinforce that our resistance, the financial resistance, has been recognized nationally and internationally. We were the first hospital in Latin America to conquer the JCI Enterprise Accreditation, which shows our standardization in quality of assistance and our management.

We would like to grow as a network, that generates assistance value and not as just a set of hospitals. We had the prize of seeing the Hospital Mater Dei Santo Agostinho as world's best specialized hospitals in 2027, amongst the best of the world in cardiology. The Mater Dei Santo Agostinho had reached the best level, the last placement in Minas Gerais, making it clear that we are the main center of assistance in the state.

According to Anahp, we rectified our trajectory connected with integrity and ethics to finalize the third quarter of 2026, proved that our strategic discipline not only brings resilience, but it can overcome historical barriers. We will continue to be focused on adequate mix, operational efficiency, on our relationship with the main stakeholders of the market, keeping the Rede Mater Dei as one of the protagonists in the sector of Brazilian supplementary health. Thank you very much. Now I will pass the floor to Rafael Cordeiro to detail our financial numbers.

Rafael Cordeiro
CFO and Director of Investor Relations, Hospital Mater Dei

Good afternoon, everyone. It is a pleasure to be part of another earnings call. Let me go over the numbers from the third quarter of 2026. As we explained, we are very proud because these results come with a lot of effort, but we would never be able to do this if we didn't have a company that was focused on reaching these results in an environment that many times is harmful, and we were able to get excellent results.

Going into the presentation at this moment, I will go to the operational highlights, which is page four. Our occupation rates are high, just like the last semester, 8 percentage points above the quarter of the previous year. We also opened 14 new beds. This increase represents 1% of the increase in the beds of the Rede Mater Dei . I will highlight the number of day patients. We reached 88,511 day patients, in line and higher than the last quarter, and also 1% higher than the previous year.

I would also like to highlight that we also had the increase of 1% for us to get to the next page, connecting to our main results. Our results for growth have come from expressive growth in our average ticket. On page five, in revenue, starting with the slide on the left, we grew our average ticket from 14.6% to [inaudible] . With the previous quarter, it's of relevant 6.5%.

This comes because of two main reasons. Of course, if we unpack this in our analyses, there may be many reasons, but it's especially because of the growth of high complexity led by oncology, but also very strongly because of our surgeries, and also because of growth in which Salvador and Nova Lima now have a proportionate percentage in the company more than they had before.

These perspectives for hospitals and oncology centers are very positive for the sustainability of our company. This was the support of our revenue, which reached BRL 660 million. A company with more than BRL 6 billion and BRL 660 million represents a growth of 7.6% over the previous quarter and 16.3% over the same quarter of the previous year. Almost BRL 100 million more over the last year in one quarter. This is a lot of growth for the size of the Rede Mater Dei. Going on to the next slide, costs and expenses, slide six. We were able to get growth in our gross margin for the first time.

In the first quarters, we were able to go from 30% before, we were around 30.5%, and we went to 31.7% growth of 1.6 percentage points compared to the previous year, in which we know there is a dilution of all of the lines that we have in the costs, minus the medication bar, because today we have a higher percentage of oncology in the company.

In our company, we have more oncology, so oncology has a bigger driver, both for the medical transfers as well as medication. All of the lines were diluted, and medications had a slight increase. But in the sum of all of these revenues, we had an improvement of 1.6% in relation to the previous quarter. Going down to the costs, we had a bit of a worse result, but we had a few drops.

We made an evaluation of our network through RFID, where we were able to identify that we needed to do a deep verification of our equipment. This is essential, and it happened now in the first semester. We had an increase of PDD in relation to the previous year. Sometimes there are operators that have some difficulties, but we do not work with them anymore, and they were done in the year of 2025, in which there was some harm in relation to the previous semester.

We had the positive impact in the previous semester for acquisitions of companies. Sometimes we have a collection of all of the costs that the company needed to spend in order to cover the past issues, and when we count this, so we include the acquisitions, and then this is shown in the results, and it drops the value that we had.

When we come back to the results, it is positive at the moment in which we collect it, and then that number is offset with the accounts payable of the company. As I said, we reach page seven, our EBITDA. That does not have any adjustments this semester, [BRL 640 million], with 2.5, 11 in margin, in line with the last year, but with a growth of BRL 1 million.

As we said, we are a company that is receiving BRL 600 million, annualizing BRL 566 million, which is the level that we have, with the perspectives that we have of ticket and of revenue for the next semesters. Compared to the previous quarter, it is BRL 11 million, but last year it is BRL 27 million, so almost multiplying in terms of EBITDA. Going on to the slide number eight, net profit. This is the reflection that we have seen in EBITDA.

We are a company that generates cash, diminishing our financial costs. We have had the growth of BRL 97 million in our net profit, very relevant. When we look at the previous year, we have a growth of 50%. Looking at the profits of the second quarter, adjusted with BRL 7 million at the time because of the renegotiation of debentures.

But if we look at the EBITDA without that adjustment, we grew almost 100% from 27 to 52. But if we look at it the way we believe that we adjusted in the past with the reason for the operation, we have grown on 50.5% year-over-year. This is also reflected in our EBITDA margin of the company, 7.9%, leaving 6.1, and then 6.3. So we advanced 0.6 percentage points, with a margin that has been growing quarter-over-quarter.

As you can see, I noticed BRL 9 million in EBITDA, and we have BRL 7 million more in net profit. It is a very interesting conversion of EBITDA in profit, and this profit, as we will show to you, has generated cash and diluted a lot of our costs. On the right side of this same slide, we have the main components of our gross capital, of our working capital.

We have a stock, consistent stock of 45 days and a slight increase of two days in the PDT. Today, our working capital is very controlled in the company. We continue to seek improvements, but today we have results that are quite satisfactory in order to generate cash. Going on to our last slide, cash and indebtedness. On the top part, we can see our cash flow. In operational cash flow, we have BRL 41 million.

For cash generation, we have had a quarter higher than the average. We made a few improvements in our units, and we made investments in our area of education, and we also bought a few cash equipment. We had an outlier in our level of investment per quarter. This quarter was higher, which made our cash post-investment negative, but within normality if we analyze the investment, splitting it into the quarters, and it will not repeat in this level for the next year.

We have positive cash generation for the rest of the year. Extraordinary events. We had to pay 40 million of our debenture, so our cash had BRL 416 million in profit, and we always highlight the repurchasing of shares, BRL 4 million more, and then BRL 4 million in the acquisition of companies. This cash of BRL 416 million aligned to BRL 1 billion .

We have a good relation of EBITDA net debt. We left 1.8 a year ago, went to 1.5 in the previous quarter, and 1.4, as I mentioned, to a debt that is below the cost of CDI. We have the debentures, 2031 and 2032, and we have the BNB, which is another relevant debt that will expire in 2034. Finally, highlighting the reduction of BRL 30 million, we are already 69% in reduction until now.

If we look at the dividends, it would be a reduction of direction for the shareholders, but it shows our resilience and our capacity to generate debt, to generate profit, sorry. I finalized my presentation, and now I will go on to our questions and answers. I would like to invite Flavio Yoshida from the Bank of America to present his question.

Flavio Yoshida
Analyst, Bank of America

Hello. Good afternoon, everyone. I have two questions. The first is in relation to the average ticket. That was a point that came up a lot. You mentioned a series of factors that positively impacted the ticket. There was a lot of readjustments, like in Mater Dei Nova Lima. When we look at all of these factors, when we look at what most contributed to that ticket, what should we expect when we look at 2027?

Should the growth be as robust as we have seen recently in this year? My second question, in regards to EBITDA margin, it is quite stable, and whether ticket is going well with the maturity of the hospitals, do you see a space for margin expansion, or is this level something that we should consider normal for the company?

José Henrique
CEO, Hospital Mater Dei

Thank you, Flavio, for those questions. I will pass the floor to Rafael.

Rafael Cordeiro
CFO and Director of Investor Relations, Hospital Mater Dei

Well, there are two main aspects that explain what we are observing. The first is the disproportional revenues besides the beds. When we consider that, we grow double when we consider our growth. In oncology, we have done a lot of movements in all of the regions and all of the units with a huge capacity with our clinical body.

We have physicians that are highly well-known in their areas of operation, and this also attracts us having oncology integrated to hospitals, where we have the generation of patients in our own units, and we are able to have journeys of care that are more integrated with other solutions, increasing our capacity to service. The movements in oncology were not in maturity.

We had many groups that are not in our vision operating in their maximum capacity, and we would like to see this happening in these next months, and certainly in the next year. You also talk about Mater Dei Nova Lima and Mater Dei Salvador, and it is quite notorious because these are young units where most of the main investments were done in the last few years, so they are not close to their maturity levels yet.

We have been increasing this as long, but the clinical body was able to attract more patients, and we can deal better with better solutions. These units provide higher tickets because of the mix of operators that they cover and also because of the mix of procedures that they provide. This is what has been positively impacting us. It is good to work every day to increase our margin.

Without many expectations in the short term for us to drastically change the level of our margins. The margin of 22.5% is very comfortable, but we would like to continue growing in revenue, and in this way, growing our EBITDA and net profit in the Rede Mater Dei . This is what we have done to grow without any issues. That way, we can be very incisive in the control of several rubrics which may impact more incisive growth on fronts that we consider relevant and strategic so that we can take over the market.

José Henrique
CEO, Hospital Mater Dei

Flavio, good afternoon. Just to look at a few things, you talked about the things that we see in the company. We have the capacity for growth in these communities and capacity for growth proportionate to the Rede Mater Dei , but it is still smaller than the number that we think we can reach. Oncology has a virtuous cycle. It does not generate revenue on its own, but it also brings more revenue, so it brings along with it the image and the surgical part.

This is very positive for the company. From the point of view, the marginal point of view, and of absolute numbers, there is a consequence to having a larger company diluting the cost from which we are able to have absolute growth. With the generation of costs, answering your question, you asked the question on EBITDA, you would have the capacity to generate profit very interestingly, with a very interesting perspective for the company.

Flavio Yoshida
Analyst, Bank of America

Thank you so much for that complete answer.

Rafael Cordeiro
CFO and Director of Investor Relations, Hospital Mater Dei

Now BTG, Eduardo can ask his question.

Speaker 5

Hello everyone. Good afternoon. Here we have [inaudible]. Two questions here on our end. On the scale six by one, could you comment if you did any exercise on possible impacts on your personnel costs and what could be absorbed in gains of productivity and reducing the days that your personnel works?

Biocor, more recently we had an announcement that Abrantes, which is the partnership with Rede D'Or, was going to be broken. I would like to understand your vision on the evolution of the competitive environment in Belo Horizonte market. Do you have any concerns on this, on potential changes, on flows of clients or commercial relationships with these two operators? Thank you so much.

José Henrique
CEO, Hospital Mater Dei

Eduardo, thank you so much for your questions. I will start by answering in relation to six by one. We've worked very hard to minimize the impacts that we found in our units. On the assistance aspect, we have many work shifts which respects the rules that are being placed, still with opportunities which we have to increase productivity, especially automatizing a few functions, some schedules of functioning of services, and remanagement of one area to another. There would be no greater impact.

This demonstrates to the unions the main impacts that they may have if we are not able to negotiate a few specific points. We have worked so that the impact is lower, depending on a few conversations that we need to have during this period until December 16. We have one more month to be able to make the necessary adjustments and have the conversations that are necessary, and to give them all rest days on Saturday. We've been working on this for a long time already, so we've made several equations, thinking about models of hiring to improve the financial impact that we have in our units. Thank you.

Rafael Cordeiro
CFO and Director of Investor Relations, Hospital Mater Dei

The second point on the competitive analysis. We've seen some movement. We did not observe any kind of change related to any kind of change. We've seen the growth of the network, Mater Dei Nova Lima. We see the numbers that we need to share with you. We have a hospital that didn't suffer these last few months in terms of losing clients. It's a hospital that grows in terms of growth and of patients. We see this as very positive in our area. They reach the niche of patients that we take care of in our institution.

In a competitive dynamic that is more positive, making investments in the market that we are in, we see that these operators are looking at these markets as very interesting markets, growing the number of lives so that these lives may grow and use our units. We have models that are sustainable with good relationships with all operators, SulAmérica and Bradesco. We have reinforced that in the end, this could be very positive.

Speaker 5

Very clear. Thank you.

Rafael Cordeiro
CFO and Director of Investor Relations, Hospital Mater Dei

I would like to invite Vinicius Figueiredo at Itaú for his question.

Vinicius Figueiredo
Analyst, Itaú

Thank you for the question. Very quickly, I would like to ask, the first thing would be in relation, I mean, even the question of their colleague about 2027, but on another angle here. We are undergoing a scenario of a lot of uncertainties, especially in the macro scenario.

Some payers, I mean, the industry became more profitable over the years, but it's actually not true for all of them. I would like to understand by looking at the profile of the payers that you have, both in Belo Horizonte and the rest of Brazil, what have you done to protect yourselves from payers in a more difficult scenario that are in debt or have capital restrictions? How much is this seen as a risk, even if it's small, looking towards the year of 2027?

The second point would be on oncology. A great player that has been important in the last quarters, it comes from one of the payers which we saw had a strong migration, and we can understand that there is a migration here in Nova Lima and Salvador, as you commented. But how much potential does still exist in the competitive scenario?

If I could speak, I would like to hear from you on your expectations for migration for the new tax reform regime, especially looking at 2027 as the entry of PIS/COFINS. If you could comment on your first visions and first calculations, it would be very interesting for us. Thank you.

José Henrique
CEO, Hospital Mater Dei

Vinicius, your first two questions will be answered by Rafael. In 2027, we are following the competitive dynamic and the dynamic of the operators. I would say that for 2027, for two years already, we have been very concerned with providers, operators that sometimes may give us some difficulties in order to see the capacity of payment of their capacity of payment, and operators which, in the end of the day, we need to have a credit analysis. Many times in the financial cycle, we have credit for a few operators that we cover.

We have been very diligent in this sense, taking care of the relationship of prepayments and other operators with a different vision in terms of the financial capacity, being very selective with new registries. In Rede Mater Dei , there are operators that have higher capacities and who have improved their financial indexes. This has been very positive. This has been good for Mater Dei when compared to two or three years ago.

We are very happy to see that we have done more business with operators that are better positioned. For next year, we believe that there will be a possibility in the competitive dynamic of these operators that are better financially positioned to grow in their share. Other operators that are in the line of operations or who are new and try to gain market are being left along the way and are losing lives.

When you look at ANS data, there was an inversion. The operators that are more partners of Hospital Mater Dei, in the last period, they grew a lot in numbers of life in detriment of others. We did not observe this in the last years. Selectively, this could improve the market dynamic and consolidate the market. That way, we would have the capacity to help us sell more lives when we talk about oncology.

Another thing I would like to highlight, because I already talked about this previously, in our vision, the groups that will be differentiated are those who are able to generate patients and have oncological journeys that are more effective and bringing reference oncologists that can be connected to these platforms that are capable of generating patients.

This is always what we defended, and this is becoming more clear now, not only in our platform, but in platforms such as ours that have capacity for growth. We have good medical references of high level for our strategy, and they have helped us. As I said, in our vision, we are still very far from the level of maturity which we can reach in oncology. We hope that next year, we can continue on these levels of growth, which we have shown this year. I will pass the floor to Rafael to talk about the reform. Rafael will talk about the tax reform.

Rafael Cordeiro
CFO and Director of Investor Relations, Hospital Mater Dei

The issue of oncology and issues of capacity is not only, besides what José Henrique said, it does not depend on the market share. It depends on the capacity that the physician have. A lot of doctors that just joined, they haven't reached their school levels of being able to provide services within our network, so we are very comfortable with the qualified team that we have, and we are very happy to be able to generate more revenue. CBS is increasing from 9.3 to 12.3. That will be discussed in the Senate.

We are a company that is prepared for this process. We don't have a sectorial vision, but an economic vision that's from Brazil as a whole. If you generate services, you can have many areas, so a very relevant aspect has to do with labor force. There are many discussions. Either you show what the reform is, keeping the price of the service product that you are buying to see what the size of the taxes are on our end, Vinicius.

I think I already mentioned this before. Today, we do not have any payments of ICMS, any service renderers. We have the substitution of PIS/COFINS by CBS. If we work with range of 9.3, which is what was estimated, of 28% in the full chart, 9.3 would be a discount in the health sector. It's a PIS/COFINS of 3.65. With a discount of 7%, we are talking about 4.62 to 4.64.

For those of us who already paid 3.65% , the challenge is the 0.08% from the point of view of the impacts in the first moment. For health, the main challenge would be IBS, because then we would be talking about taxes that we do not have and that we should deal with in the chain in a very strategic way for the products that we buy.

The generation and analysis of credits as a whole. Of course, I'm simplifying the issue on the first moment, but anyone at the time of difficulty in the tax reform, those who do not have ICMS in the first moment, would not have any chance to make any mistakes. There will be no mistakes initially. Things are changing a lot, so we need to present numbers to be able to negotiate.

Even the prepared companies are suffocated, adjusting everything and stuff. We do see the positive side. It's a sector that could be neutral to positive as a whole. The first moment, it's not so important, but there's a moment where we are more within the average of those who are prepared to be able to negotiate. I am not sure what the approach is. It's more like looking at a whole.

I made an analysis that was more general, which is the reform, but also bringing this into our field in terms of operations. For the first moment of the reform, if anything was not clear, if you want to explore anything, I'm available.

Vinicius Figueiredo
Analyst, Itaú

Everything was so clear. Thank you so much for those complete answers. Thank you, Rafa.

Rafael Cordeiro
CFO and Director of Investor Relations, Hospital Mater Dei

Thank you. Gustavo Miele, please go ahead.

Gustavo Miele
Analyst, Goldman Sachs

Hello, everyone. Thank you so much for the call. I have two questions as well. First of all, Vini's question on ticket. We've had a great relationship with your conversations with the payers, and he commented in the beginning of the call on the complexity to adjust the ticket. Could this high penetration that you are seeing, is it so important if it's serving as a exchange to have a commercial relationship that's more flexible? Less analysis. Has this given you new registries?

Have you been able to work with better partners that are with you for some time? That would be a first question. A second point. One more macro point. The increase of interest rates, of course, impacts the allocation of capital for 2027. How do you- interest rate? So maybe this could be an excellent level. Thank you so much.

José Henrique
CEO, Hospital Mater Dei

Thank you, Miele. Well, to try to answer your question, with the operators, we speak case by case, depending on what are the products, what are the needs of the operator, and depending on that, we have hospitals that have characteristics that bring together several products of different operators. Our competitive advantage has always been a differential of us having adequate cost control and invest strongly in efficiency. So yes, we have been able to cover some operators in products of lower tickets.

Recently, we spoke on the Efetivo Plus with Bradesco and Salvador. We went to Salvador to register that. We've also done the registries of other restrictive networks with the market operators in Uberlândia. In the same way, we have been able, with the local culture, to directly reach companies that are gaining in volume in the restrictive networks, providing services with quality and efficiency. In oncology, it's the same.

As we grow the volume of oncological volume, we begin to access a different range of the relationships with the industry. We have also worked to share that relationship that we have with the operators to be more cost-effective. It becomes a positive spiral. This is how we have worked, and we will always be flexible in order to operate with the different providers in their needs in terms of full capital allocation. Of course, we are so concerned.

As we have always commented, our main strategic priority has been deleveraging ever since the beginning of the company and our level of vision. We are very comfortable, which is 1.5x . We would like to generate more economic margins, and with that. With the operators that have betas that, we will generate more cash, which will help us to deleverage, generating a lot of strategic capacities.

This will help us rebuying and having a policy of dividends that's a bit different that we've had in other years. Of course, we have a few M&As for some hospitals that may generate value, additional value, that can be strategic opportunities for the company. To make it very clear, our first priority at this moment is to maintain this deleveraging rhythm.

Gustavo Miele
Analyst, Goldman Sachs

Very good, José Henrique. Thank you for your answers.

Rafael Cordeiro
CFO and Director of Investor Relations, Hospital Mater Dei

XP can now ask their question.

Speaker 8

Hello, everyone. Two questions connected to oncology. Two points. What's the percentage of your revenue that is connected to your oncology, if it's growing double in oncology? But just to understand the impact in terms of margin when we connect with MatMed grew a lot, and you commented on that.

They have a mix of oncology that's quite heavy, but it's just to understand if oncology tends to have a more pressured margin, not only in consolidated, all of these technologies come in. Just to understand, today you have a margin that's more pressured. That's why it's reflected in a higher MatMed, or does it make sense to think about an expanded margin of oncology connected to the revenue, which should be higher? Those are the two points.

José Henrique
CEO, Hospital Mater Dei

Thank you, Fernando, for your questions. Well, we still do not open the percentage of oncology for all of our hospitals because we do have very different relationships between them. Over time, we would need to understand how we will disclose the information.

In oncology, of course, over the next years, we will bring more information to have a better idea of how much that represents in oncology for the Rede Mater Dei , I think. In your own question, you brought in challenges of the oncological line. Yes. Some therapies have lower margins with tickets that are high and lower margins. What I can tell you is the following today.

We have tools in the institution to help us manage this in a very close way, including, of course, pharmaceutical industries in discussion so that we can create models in which they participate in the risk, be they risks related to the inclusion of new technologies and new therapies, be they risks related to dosages, because in the end of the day, it impacts all these negotiations.

As I said, we also, when we buy more, we will be able to improve our margins over time. That's why in the previous question, we do not have at this moment any kind of guidance on increase of margin, percentage margins, given these challenges of managing a company that grows disproportionately in different lines than what we grew with today. Well, that's what we want to make very clear.

We intend to grow in these levels of margins, but to grow and generate new negotiations. The vision of the assistance points from certain protocols, negotiations with operators, so that on the oncological line also after grow in margin percentages. I think there's space in the future for us to really evolve, but not in the short term.

Speaker 8

Thank you. Excellent. That was very clear.

Rafael Cordeiro
CFO and Director of Investor Relations, Hospital Mater Dei

We have closed our question and answer session. Thank you so much to everyone who participated, and Henrique has the final words.

José Henrique
CEO, Hospital Mater Dei

Once again, sorry for my voice, but I think we were able to answer a lot of questions, and we are 100% available to improve, to deepen in any of the questions. The reports are all out. We have no doubts that we have built in the short term the necessary basis so that we can grow. Discipline and execution is the most relevant part that we have in our company at this time.

We see that discipline and the execution of each one of our units has reinforced the interest of medical teams, the interest of health plans, and mainly the interest of the patients to look for the Mater Dei for the solutions of their needs, be it through doing business with us or reaching their needs. We are very satisfied with the results of this quarter, with the clear feeling that a lot still has to be built. Thank you, each one. We are available. Thank you.